AIC
IBRX icon

Archer Investment Corporation’s ImmunityBio IBRX Stock Holding History

Archer Investment Corporation’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45K Buy
5,872
+2,358
+67% +$16.1K 0.01% 544
2025
Q4 		$6.96K Hold
3,514
– – ﹤0.01% 797
2025
Q3 		$8.64K Buy
+3,514
New +$9.05K ﹤0.01% 748

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Archer Investment Corporation's IBRX Position: Q1 2026 in Review

Archer Investment Corporation increased its ImmunityBio (IBRX) stake by 67% in Q1 2026, buying an estimated $16.1K and bringing the position to 5,872 shares worth $45K. The position accounts for 0.01% of the portfolio, ranked #544.

Archer Investment Corporation first reported a position in IBRX in Q3 2025 and has held it in 3 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Archer Investment Corporation held 5,872 shares of ImmunityBio worth $45K as of Q1 2026.
  • Archer Investment Corporation bought 2,358 ImmunityBio shares in Q1 2026, an estimated $16.1K.
  • ImmunityBio made up 0.01% of Archer Investment Corporation's portfolio in Q1 2026, its #544 holding.
  • Archer Investment Corporation first reported a position in ImmunityBio in Q3 2025 and has held it in 3 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Archer Investment Corporation's 13F filing for Q1 2026, filed 4 May 2026.